It wouldn't be surprising to see some C-met deals coming. I recently started nibbling on both SGXP and ARQL, and figure that even without an imminent deal, they're likely good long term holdings.
>>> ARQL-OP-bet you see a decent trade in the stock in the next few weeks. Howard Liang expects SGXP (not rated) to announce a partnership on their preclinical C-met inhibitor this summer. Hearing there are 10 term sheets out for SGXP drug and shaping up to possibly be the richest preclinical biotech deal ever. ARQL's ARQ-197(c-MET inhib entering ph 2-pancreatic cancer mid:07) is currently partnered only in Jap. Expect the SGXP deal to significantly raise awareness of c-MET class and could be 9 bidders walking away from bidding looking to license a c-MET. T =$12. <<<
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM